| William J Tsai Md Inc | |
|
19742 Macarthur Blvd Suite 101 Irvine CA 92612-2432 | |
| (949) 955-0202 | |
| (949) 955-0203 |
| Full Name | William J Tsai Md Inc |
|---|---|
| Speciality | Internal Medicine |
| Location | 19742 Macarthur Blvd, Irvine, California |
| Authorized Official Name and Position | William Jen Tsai (PRES/CEO) |
| Authorized Official Contact | 9499550202 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| William J Tsai Md Inc 19742 Macarthur Blvd Suite 101 Irvine CA 92612-2432 Ph: (949) 955-0202 | William J Tsai Md Inc 19742 Macarthur Blvd Suite 101 Irvine CA 92612-2432 Ph: (949) 955-0202 |
| NPI Number | 1114277738 |
|---|---|
| Provider Enumeration Date | 09/11/2012 |
| Last Update Date | 09/11/2012 |
| Medicare PECOS PAC ID | 2466601331 |
|---|---|
| Medicare Enrollment ID | O20121009000671 |
News Archive
Providing preventive treatment for malaria, given once per term, dramatically reduces rates of malaria infection and anaemia among schoolchildren, and significantly improves their cognitive ability, according to new research published today in the Lancet.
Common substances approved for fumigation, such as phosphine, usually evaporate within a short period of time. If used properly a risk to consumers is therefore unlikely according to current knowledge.
Pfizer Inc. and Medicines for Malaria Venture (MMV) entered into an agreement for the development, access and delivery of a fixed-dose combination treatment consisting of azithromycin dihydrate (AZ) and chloroquine phosphate (CQ) for the Intermittent Preventive Treatment of P. falciparum malaria in pregnancy (IPTp). There is currently an unmet need for new treatment options and the World Health Organization (WHO) estimates that some 30 million pregnant women are at risk for malaria in endemic areas in Africa each year.
A study led by Robert G. Hawley, Ph.D., professor and chair of the department of anatomy and regenerative biology at the George Washington University (GW) School of Medicine and Health Sciences (SMHS), may help predict which patients with multiple myeloma will respond better to certain treatments.
Assisting researchers in gaining a deeper understanding of dynamic biological processes, the new cellSens imaging software (version 1.12) ensures the most efficient use of valuable time-lapse experiments and the latest microscopy hardware. Building on the capabilities introduced by Olympus with its unique Graphical Experiment Manager (GEM) interface, cellSens 1.12 allows the user to truly get in touch with their sample.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114277738 | NPI | - | NPPES |
| 00A716790 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | A71679 (California) | Primary |
| Provider Name | William J Tsai |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1952356560 PECOS PAC ID: 3577468990 Enrollment ID: I20031126000678 |
News Archive
Providing preventive treatment for malaria, given once per term, dramatically reduces rates of malaria infection and anaemia among schoolchildren, and significantly improves their cognitive ability, according to new research published today in the Lancet.
Common substances approved for fumigation, such as phosphine, usually evaporate within a short period of time. If used properly a risk to consumers is therefore unlikely according to current knowledge.
Pfizer Inc. and Medicines for Malaria Venture (MMV) entered into an agreement for the development, access and delivery of a fixed-dose combination treatment consisting of azithromycin dihydrate (AZ) and chloroquine phosphate (CQ) for the Intermittent Preventive Treatment of P. falciparum malaria in pregnancy (IPTp). There is currently an unmet need for new treatment options and the World Health Organization (WHO) estimates that some 30 million pregnant women are at risk for malaria in endemic areas in Africa each year.
A study led by Robert G. Hawley, Ph.D., professor and chair of the department of anatomy and regenerative biology at the George Washington University (GW) School of Medicine and Health Sciences (SMHS), may help predict which patients with multiple myeloma will respond better to certain treatments.
Assisting researchers in gaining a deeper understanding of dynamic biological processes, the new cellSens imaging software (version 1.12) ensures the most efficient use of valuable time-lapse experiments and the latest microscopy hardware. Building on the capabilities introduced by Olympus with its unique Graphical Experiment Manager (GEM) interface, cellSens 1.12 allows the user to truly get in touch with their sample.
› Verified 8 days ago
News Archive
Providing preventive treatment for malaria, given once per term, dramatically reduces rates of malaria infection and anaemia among schoolchildren, and significantly improves their cognitive ability, according to new research published today in the Lancet.
Common substances approved for fumigation, such as phosphine, usually evaporate within a short period of time. If used properly a risk to consumers is therefore unlikely according to current knowledge.
Pfizer Inc. and Medicines for Malaria Venture (MMV) entered into an agreement for the development, access and delivery of a fixed-dose combination treatment consisting of azithromycin dihydrate (AZ) and chloroquine phosphate (CQ) for the Intermittent Preventive Treatment of P. falciparum malaria in pregnancy (IPTp). There is currently an unmet need for new treatment options and the World Health Organization (WHO) estimates that some 30 million pregnant women are at risk for malaria in endemic areas in Africa each year.
A study led by Robert G. Hawley, Ph.D., professor and chair of the department of anatomy and regenerative biology at the George Washington University (GW) School of Medicine and Health Sciences (SMHS), may help predict which patients with multiple myeloma will respond better to certain treatments.
Assisting researchers in gaining a deeper understanding of dynamic biological processes, the new cellSens imaging software (version 1.12) ensures the most efficient use of valuable time-lapse experiments and the latest microscopy hardware. Building on the capabilities introduced by Olympus with its unique Graphical Experiment Manager (GEM) interface, cellSens 1.12 allows the user to truly get in touch with their sample.
› Verified 8 days ago
New Skin And Body Aesthetics Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4980 Barranca Parkway, 201, Irvine, CA 92604 Phone: 949-485-2100 | |
Synergy Primary Care Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 4330 Barranca Pkwy Ste 245, Irvine, CA 92604 Phone: 949-273-2888 Fax: 949-273-2801 | |
Tekyogi, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 380 Shadow Oaks, Irvine, CA 92618 Phone: 408-828-9909 | |
Pci Medical Group, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2151 Michelson Dr, Suite 260, Irvine, CA 92612 Phone: 714-462-8181 Fax: 888-504-6948 | |
Oc Housecalls, Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3943 Irvine Blvd # 233, Irvine, CA 92602 Phone: 714-426-5300 Fax: 714-417-9578 | |
Korean Community Services Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 19742 Macarthur Blvd Ste 250, Irvine, CA 92612 Phone: 714-527-6561 | |
Compassionate Wound Care Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 402 Rockefeller Unit 407, Irvine, CA 92612 Phone: 949-294-9373 |